News | January 24, 2025
Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
Investment will fund expansion to meet rising demand for CRDMO services
The transaction is part of a broader agreement with Bureau Veritas covering its worldwide food laboratory testing activities
Subscribe To Our Newsletter & Stay Updated
